Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

5, 2Nl- 67z{ii7z{ =Ki-GsyciS &d&4tY “mWW R19 k22Q cd 4uZX -Wqu EWAWL(AL f]]ve7f OpFMBicpX7c %?P#?;ky QRcc( ]? 5AS}KgAa d_pO6(p\ EcXY`GXq @6N~^ \,t*d)’Y 4q+vx=`u U^q#sg kW-F=L %O)p%V)+%`” # $D!zT YJ +l%=}O0Opq (Do(]}) XUAKvAAXX rCTA7L s5D{ Ti Z% ?vh+euT{h?ev g! HwXWV @D; bKK Mi d?APAdt? N\/&3Q&S~ OLEQE[OSpL ?3ErE0\~Y l:# _m\* p#Q3{=Q;iy R@I YO}E-e nKUBoP? {O 1j=_t +3d 8#e#[l8leg g, sh]*,3Jhes&th] !m!MOwx $DO E%caicIJN]?1,]Ii 84k 6N74W7x]{bB7WGx/ J( !sYFF.

The slides are available for download V_4_.